Comments to FDA: Proprietary Name Reservation for Drug Products

Share page:

Comments | Oct 27, 2014

Docket Number:
FDA-2014-N-1008

In principle, CHPA supports an early approval program for proposed proprietary drug names. However, should FDA decide to implement a program, we expect that FDA would publish a draft Guidance for Industry and we would provide further comment based on the criteria.